Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Medacta Group SA is a Swiss-based medical device company specializing in the development, manufacturing, and distribution of orthopedic and neurosurgical products. Founded in 1999 by Dr. Alberto Siccardi, an orthopedic patient, it is headquartered in Castel San Pietro, Switzerland, and operates in over 60 countries across Europe, North America, Asia-Pacific, Latin America, and the Middle East and Africa. The company offers innovative solutions for joint replacement surgeries including hip, knee, and shoulder systems, as well as spine surgery, sports medicine, and revision procedures. Notable features include personalized 3D planning tools like MySolutions, patient-matched technologies such as MyKnee and MyHip, and advanced materials like HighCross and 3D Metal, emphasizing minimally invasive techniques and kinematic alignment for improved patient outcomes. Medacta Group SA supports surgeons through its global M.O.R.E. Institute for medical education and focuses on sustainable innovation. With approximately 1,907 employees, it generates significant revenue from medical products, playing a key role in the healthcare equipment sector by advancing personalized and efficient surgical solutions worldwide.
16.29% operating margin is respectable but not wide. ROIC at 13.78%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 15.8%, still solid.
Net debt of €228M represents 23.8x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
€684M
▲ +15.8% YoY
Net Income (TTM)
€95M
▲ +31.0% YoY
Op. Margin
16.29%
▲ +0.9pp YoY
ROIC
13.78%
▲ +0.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€10M
▲ +289.6% YoY
Op. Cash Flow (TTM)
€51M
▲ +27.1% YoY
Net Debt
€228M
Cash & Equiv.
€33M
3Y CAGR: +18.7%
3Y CAGR: +65.7%
Continue Research